Vivos in The News Explore The Stories Investor RelationsLeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Menu Investor RelationsLeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Listen to the live Webcast for Our First Quarter 2024 Earnings Call Vivos Reports First Quarter 2024 Financial Results & Provides Operational Update Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway” Load More
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA